Vertex Pharmaceuticals Incorporated Share Price

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 20/06/2024 BST Pre-market 12:05:00
471.4 USD +0.88% Intraday chart for Vertex Pharmaceuticals Incorporated 471.4 +0.01%
Sales 2024 * 10.75B 851B Sales 2025 * 11.67B 924B Capitalization 122B 9,627B
Net income 2024 * 3.96B 313B Net income 2025 * 4.46B 353B EV / Sales 2024 * 10 x
Net cash position 2024 * 13.97B 1,106B Net cash position 2025 * 18.59B 1,471B EV / Sales 2025 * 8.83 x
P/E ratio 2024 *
31.4 x
P/E ratio 2025 *
28.1 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.9%
More Fundamentals * Assessed data
Dynamic Chart
Vertex Pharmaceuticals Has Pricing Accord for Cystic Fibrosis Drugs With UK National Health Service MT
Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 MT
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials MT
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on CASGEVY (Exagamglogene Autotemcel) CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
RBC Adjusts Price Target on Vertex Pharmaceuticals to $421 From $424 MT
Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients MT
Vertex Pharmaceuticals Incorporated Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
More news
1 day+0.01%
1 week-1.60%
Current month+3.52%
1 month+5.72%
3 months+14.38%
6 months+17.77%
Current year+15.85%
More quotes
1 week
463.23
Extreme 463.23
479.15
1 month
435.57
Extreme 435.57
486.43
Current year
391.01
Extreme 391.01
486.43
1 year
335.82
Extreme 335.82
486.43
3 years
176.36
Extreme 176.36
486.43
5 years
165.23
Extreme 165.23
486.43
10 years
64.72
Extreme 64.72
486.43
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 31/01/17
Chairman 68 07/07/09
Director of Finance/CFO 56 09/04/19
Members of the board TitleAgeSince
Director/Board Member 68 07/06/17
Chairman 68 07/07/09
Director/Board Member 64 31/12/97
More insiders
Date Price Change Volume
20/06/24 471.4 +0.88% 1,409,844
18/06/24 467.3 -1.35% 1,230,804
17/06/24 473.7 -1.46% 1,190,217
14/06/24 480.7 +0.35% 640,792
13/06/24 479 +0.68% 808,498

Delayed Quote Nasdaq, June 20, 2024 at 09:00 pm

More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4 USD
Average target price
463.4 USD
Spread / Average Target
-1.69%
Consensus